See more : Essity AB (publ) (ETTYF) Income Statement Analysis – Financial Results
Complete financial analysis of Celltrion Healthcare Co., Ltd. (091990.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celltrion Healthcare Co., Ltd., a leading company in the industry within the sector.
- Getinge AB (publ) (GNGBY) Income Statement Analysis – Financial Results
- Infineon Technologies AG (IFNNF) Income Statement Analysis – Financial Results
- Gimv NV (GIMB.BR) Income Statement Analysis – Financial Results
- Royal Caribbean Cruises Ltd. (0I1W.L) Income Statement Analysis – Financial Results
- Columbia Sportswear Company (COLM) Income Statement Analysis – Financial Results
Celltrion Healthcare Co., Ltd. (091990.KQ)
About Celltrion Healthcare Co., Ltd.
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd. in March 2009. Celltrion Healthcare Co., Ltd. was founded in 1999 and is headquartered in Incheon, South Korea.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,972.19B | 1,804.49B | 1,627.60B | 1,100.88B | 713.49B | 921.50B | 756.44B | 376.03B | 166.55B |
| Cost of Revenue | 1,410.43B | 1,373.98B | 1,085.82B | 891.57B | 644.61B | 686.20B | 529.49B | 253.95B | 89.50B |
| Gross Profit | 561.75B | 430.50B | 541.77B | 209.30B | 68.88B | 235.30B | 226.94B | 122.08B | 77.04B |
| Gross Profit Ratio | 28.48% | 23.86% | 33.29% | 19.01% | 9.65% | 25.53% | 30.00% | 32.46% | 46.26% |
| Research & Development | 17.75B | 29.23B | 29.73B | 16.68B | 13.51B | 12.04B | 7.13B | 4.12B | 2.16B |
| General & Administrative | 114.84B | 92.41B | 64.87B | 46.19B | 39.31B | 27.92B | 19.97B | 19.83B | 497.77M |
| Selling & Marketing | 176.88B | 100.41B | 80.02B | 61.22B | 39.95B | 29.83B | 16.06B | 12.03B | 27.56B |
| SG&A | 291.72B | 192.81B | 144.89B | 107.41B | 79.26B | 57.74B | 36.03B | 31.87B | 41.41B |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 326.36B | 222.62B | 221.14B | 129.84B | 49.08B | 984.04M | 30.67B | 34.84B | 44.06B |
| Cost & Expenses | 1,736.79B | 1,596.61B | 1,306.96B | 1,021.41B | 693.69B | 687.18B | 560.16B | 288.79B | 133.56B |
| Interest Income | 5.82B | 9.62B | 5.95B | 4.10B | 4.61B | 17.31B | 32.46B | 56.31B | 22.37B |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.31B | 5.12B | 2.94B | 2.06B | 324.00M | 182.00M | 178.00M | 206.00M | 191.62M |
| EBITDA | 234.20B | 204.56B | 365.05B | 84.85B | -24.88B | 165.01B | 182.90B | 84.54B | 33.43B |
| EBITDA Ratio | 11.87% | 11.34% | 22.43% | 7.71% | -3.49% | 17.91% | 24.18% | 22.48% | 20.07% |
| Operating Income | 228.89B | 199.44B | 362.11B | 82.79B | -25.20B | 164.83B | 182.72B | 84.33B | 33.24B |
| Operating Income Ratio | 11.61% | 11.05% | 22.25% | 7.52% | -3.53% | 17.89% | 24.16% | 22.43% | 19.96% |
| Total Other Income/Expenses | -22.71B | -10.20B | -52.47B | -9.85B | 48.30B | 51.49B | -19.97B | 16.27B | -22.84B |
| Income Before Tax | 229.57B | 198.26B | 314.68B | 75.36B | 24.41B | 217.01B | 163.82B | 100.60B | 10.62B |
| Income Before Tax Ratio | 11.64% | 10.99% | 19.33% | 6.85% | 3.42% | 23.55% | 21.66% | 26.75% | 6.38% |
| Income Tax Expense | 82.39B | 45.69B | 74.27B | 10.40B | 13.02B | 51.33B | 40.32B | 107.34B | 3.31B |
| Net Income | 147.18B | 152.57B | 240.41B | 64.96B | 11.39B | 165.68B | 123.50B | -6.74B | 10.13B |
| Net Income Ratio | 7.46% | 8.45% | 14.77% | 5.90% | 1.60% | 17.98% | 16.33% | -1.79% | 6.08% |
| EPS | 912.03 | 935.30 | 1.46K | 399.46 | 69.95 | 1.03K | 1.05K | -97.12 | 30.15K |
| EPS Diluted | 912.03 | 935.30 | 1.46K | 399.46 | 69.95 | 1.03K | 1.05K | -97.12 | 30.15K |
| Weighted Avg Shares Out | 161.29M | 163.07M | 164.49M | 162.62M | 162.78M | 160.89M | 117.30M | 69.40M | 336.07K |
| Weighted Avg Shares Out (Dil) | 161.37M | 163.12M | 164.52M | 162.62M | 162.78M | 160.89M | 117.30M | 69.40M | 336.07K |
Source: https://incomestatements.info
Category: Stock Reports